OncoGenex Pharmaceuticals Inc. (OGXI)
(Delayed Data from NSDQ)
$0.40 USD
-0.02 (-3.85%)
Updated Aug 2, 2017 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Achieve Life Sciences, Inc. [OGXI]
Reports for Purchase
Showing records 1 - 20 ( 67 total )
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Lowering Price Target to $8 on Negative Phase 3 SYNERGY Trial Results, Q1:14 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Q4:13 and FY:13 Results and Update; Top-line SYNERGY Data Expected by Mid:14
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
IDMC Recommends Continuing the Phase III SYNERGY Trial of Custirsen-Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
IDMC Recommends Continuing the Phase III SYNERGY Trial of Custirsen-Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Q3:13 - Awaiting SYNERGY Phase III in H1:14, Borealis-1 in H2:14, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Q2:13 - Custirsen Data H1:14, Apatorsen - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Q1:13 EPS, Broad Development Programs for OGX-427 Continue
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 29
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Achieve Life Sciences, Inc.
Industry: Medical - Drugs
Q4:12 EPS, SYNERGY Trial Likely to Read Out in H1:14, OGX-427 Progressing on Multiple Fronts, Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G